Author: Claude (AI), from PubMed abstracts · Reviewed by: Dr Mina Abdelmseih · Reviewed: 2026-11-15 · Review due: 2027-11-15

Educational content only. Not personalised medical advice. Clinical decisions remain the responsibility of the treating clinician.

Juvenile Idiopathic Arthritis-associated Uveitis

Juvenile idiopathic arthritis (JIA) is the most common chronic rheumatic disease of childhood and is associated with uveitis in up to 20-25% of cases [S8]. The uveitis is typically chronic, asymptomatic, non-granulomatous and anterior, so children must be found by screening rather than by symptoms [S8]. It is a leading cause of preventable visual loss in children [S10].

Key points - Screen children with JIA regularly; frequency should follow individual risk factors (younger age and positive antinuclear antibody at onset, oligoarticular subtype, short disease duration) [S3] [S7]. - Topical glucocorticoids are the initial treatment; methotrexate, then adalimumab, are added when systemic treatment is needed [S3] [S8]. - Adalimumab with methotrexate markedly lowers treatment failure or relapse (pooled hazard ratio 0.18) [S10]. - Stopping adalimumab after at least 1 year of control led to recurrence in 68% vs 14% who continued (ADJUST RCT) [S9]. - Management needs close collaboration between paediatric rheumatologist and ophthalmologist [S8].

Evidence last checked: 2026-10-17 (PubMed abstracts).

Red flags

• No symptoms does not mean no uveitis. Mild to moderate inflammation is asymptomatic in the initial stages [S1].
• Complications at diagnosis. Structural complications are present at diagnosis in 30% to 50% of children with JIA-associated uveitis (trial protocol background) [S1].
• Amblyopia risk. Delayed diagnosis, inadequate treatment and amblyopia contribute to the morbidity of childhood uveitis [S2].
• Missed screening. Strong monitoring recommendations were made because of vision-threatening complications with infrequent monitoring [S3].
• Flare after stopping adalimumab. Median time to failure after switching to placebo was 119 days [S9].

Recognise it: who is at risk

• By subtype. Pooled uveitis frequency was 24% in oligoarticular JIA, 12% in polyarticular JIA and 1% in systemic JIA; 9% in juvenile psoriatic arthritis and 24% in juvenile spondyloarthropathy [S4].
• Predictors. Younger age and positive antinuclear antibody at JIA onset, extended and persistent oligoarthritis, rheumatoid factor-negative polyarthritis, psoriatic arthritis and short JIA duration [S7]. Onset of arthritis under seven years of age is a major risk factor [S1].
• Geography. Uveitis in JIA was more common in Europe (14%), North America (11%) and the Middle East (12%) than in East Asia (7%) and Oceania (3%) [S4].
• Treatment effect on risk. Methotrexate and monoclonal TNF inhibitors reduce the risk of JIA uveitis [S7].

Confirm it

• The type is most often anterior uveitis (14% of JIA patients in pooled data) [S4], chronic and non-granulomatous [S8].
• Grade activity with Standardization of Uveitis Nomenclature (SUN) criteria; trials used SUN grading for success and failure [S1] [S6].
• Monitoring intervals should be based on examination findings and the treatment regimen [S3].

Manage it

Before acting on this section, check the national and local guidelines, product information and regulatory approvals that apply where you practise. See the medical disclaimer.

Tier A (primary care / no specialist)

• Every child diagnosed with JIA needs referral for ophthalmic screening, because uveitis is often silent [S1] [S3]. Children with none of the Nordic risk factors do not benefit from long-term screening [S7], but that judgement belongs to the eye and rheumatology team.
• Do not stop methotrexate or adalimumab without the treating team: stopping adalimumab caused frequent relapse [S9].

Tier B (general eye clinic)

1. Screen by risk. Examine at intervals set by risk factors; children on TNF inhibitors or methotrexate may be screened less often [S7]. Exact intervals are in the Nordic and ACR guidelines, not in these abstracts [S3] [S7].
2. Start topical glucocorticoids to control inflammation [S3]. Dosing is not covered by these abstracts: follow local formularies.
3. Comanage with paediatric rheumatology for systemic therapy [S8].
4. Watch for amblyopia and complications such as cataract and glaucoma [S1] [S2].

Tier C (specialist centre)

1. Stepwise systemic therapy. Methotrexate first, adding adalimumab if methotrexate alone is not sufficient [S8]; the ACR guideline recommends methotrexate and the monoclonal TNF inhibitors adalimumab and infliximab when systemic treatment is needed [S3].
2. Adalimumab evidence. Cochrane (3 RCTs, 134 participants, low certainty) found adalimumab increases treatment success (risk ratio 2.60) and decreases failure (risk ratio 0.23) vs placebo; evidence for etanercept was very limited [S6]. A 2026 meta-analysis of RCTs found a pooled hazard ratio of 0.18 for failure or relapse with adalimumab plus methotrexate [S10]. In SYCAMORE, adalimumab was dosed at 20 mg for patients under 30 kg or 40 mg for 30 kg or more, every 2 weeks, on stable methotrexate (as reported in [S1]).
3. When to stop. In ADJUST (87 patients controlled for at least 1 year), treatment failure occurred in 14% continuing vs 68% stopping adalimumab; all who failed regained control after restarting, with a median of 105 days [S9]. Four serious adverse events occurred, all in the adalimumab group [S9].
4. Refractory disease. Anti-IL6 agents or other anti-TNF agents such as infliximab may be considered, though evidence is limited [S8]. The 2023 MIWGUC update of SHARE provides 14 consensus treatment recommendations [S5].

Refer when

Pitfalls

• Waiting for symptoms before examining a child with JIA [S1] [S8].
• Stopping screening after a normal first examination in a high-risk child [S3] [S7].
• Stopping adalimumab once quiet without planning for likely relapse [S9].
• Overlooking amblyopia in young children with uveitis [S2].

Evidence notes

• The ACR guideline states that recommendations rest on consensus expert opinion owing to low-quality evidence [S3].
• Conflict: Cochrane initial pooled estimates using standard SUN definitions showed little or no difference, whereas trial-specific definitions showed benefit [S6].
• The trials described were run in the USA, UK, France and Australia [S6] [S9]; uveitis frequency in JIA varies by region [S4].
• Not covered by these sources: exact screening intervals, methotrexate dosing, cataract and glaucoma surgery, and access to biologics in low-resource settings.

Related articles

• Anterior Uveitis
• Biologics and Immunosuppression for Non-infectious Uveitis

References

See the numbered source list below. Each marker [S#] links to its PubMed and DOI record.